Glucagon Receptor

Post-Marketing Use of Teduglutide in a Large Cohort of Adults with Short Bowel Syndrome-Associated Chronic Intestinal Failure: Evolution and Outcomes

50 views | Sep 26 2023

This real-life study assessing teduglutide initiation and outcomes in SBS-CIF patients demonstrated its efficacy in reducing parenteral support volume and indicated a higher response rate in incident patients, suggesting a potential benefit in early treatment. [Read the Full Post]

Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists

59 views | Sep 24 2023

The study introduces compound 42, a novel 5,6-dihydro-1,2,4-triazine derivative, as a highly potent and selective GLP-1R agonist with improved efficacy, selectivity, and duration of action compared to danuglipron, demonstrating its potential for the treatment of type 2 diabetes mellitus and obesity. [Read the Full Post]

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus

27 views | Sep 24 2023

In Japanese participants with type 2 diabetes mellitus, the oral small-molecule glucagon-like peptide-1 receptor agonist danuglipron demonstrated dose-proportional increases in exposure, significantly reduced glycaemic parameters and body weight, and exhibited a safety profile consistent with its mechanism of action. [Read the Full Post]

A Case of Dulaglutide-Induced Vaginal Bleed

31 views | Sep 20 2023

Severe vaginal bleeding, a rare side effect of Dulaglutide, was observed in a perimenopausal female with type 2 diabetes mellitus, underscoring the importance of post-market surveillance to identify uncommon adverse reactions not seen in clinical trials. [Read the Full Post]

Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications

64 views | Jul 26 2023

This comprehensive review explores the added benefits and drawbacks of approved and upcoming centrally-acting anti-obesity drugs, highlighting their potential for personalized, pharmacological management of obesity and its associated complications. [Read the Full Post]

Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial

30 views | Jul 25 2023

The Glycemia Reduction Approaches in Diabetes (GRADE) trial found no significant differences in kidney outcomes when comparing the addition of different glucose-lowering medications to metformin for glycemic management in individuals with type 2 diabetes. [Read the Full Post]